// App-Quantinova.ai

8027 : Pomalidomide (POM) + low-dose dexamethasone (LoDEX) + daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure.

Researchers

Presenter

  • David Samuel DiCapua Siegel

Principal Investigators

  • Christy Joy Samaras

  • Michael Sebag

  • Jesus G. Berdeja

  • Siddhartha Ganguly

  • Jeffrey Matous

  • Kevin W. Song

  • Christopher Seet

  • Giampaolo Talamo

  • Shanthi Srinivas

  • Mirelis Acosta-Rivera

  • Michael Bar

  • Donald Quick

  • Bertrand Marquess Anz

  • Gustavo Fonseca

  • Donna Ellen Reece

  • Faiza Zafar

  • Weiyuan Chung

  • Nizar J. Bahlis

Medical Centers

  • John Theurer Cancer Centre, Hackensack University Medical Center, Hackensack, NJ

  • University of California, Los Angeles, Los Angeles, CA

  • Cleveland Clinic, Cleveland, OH

  • McGill University Health Centre, Montreal, QC, Canada

  • Sarah Cannon Research Institute, Nashville, TN

  • University of Kansas Cancer Center, Fairway, KS

  • Colorado Blood Institute, Denver, CO

  • Vancouver General Hospital, Vancouver, BC, Canada

  • UCLA Care Center, Los Angeles, CA

  • Penn State Cancer Institute, Hershey, PA

  • Veterans Administration New Jersey Health Care System, East Orange, NJ

  • Fundacion de Investigacion, San Juan, PR

  • Stamford Hospital, Stamford, CT

  • Joe Arrington Cancer Research and Treatment Center, Lubbock, TX

  • Tennessee Oncology, Chattanooga, TN

  • Florida Cancer Specialists, St. Petersburg, FL

  • Princess Margaret Hospital, Toronto, ON, Canada

  • Celgene Corporation, Summit, NJ

  • University of Calgary, Calgary, AB, Canada

Locations

  • United States

  • Canada

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • daratumumab Intravenous

  • Sparsentan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01946477

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved